Tirzepatide and semaglutide are often compared using headline weight-loss percentages. A direct randomized trial now provides useful evidence, but its result applies to the products, doses, population, and duration actually studied. It does not identify the best treatment for every person or establish equivalence between branded and compounded preparations.
This guide explains what SURMOUNT-5 found, how to read its numbers, and which other factors matter when discussing treatment. The central question is not simply which medicine produced the larger average loss, but which evidence and practical considerations fit the individual’s health goals and circumstances.
How are the medicines different?
Semaglutide activates GLP-1 receptors. Tirzepatide activates both GIP and GLP-1 receptors. These pathways affect appetite and metabolic regulation, including glucose control. The pharmacological difference provides context for research, but it does not translate into a rule that two receptor targets produce twice the benefit or fewer side effects for everyone.
Both medicines have multiple clinical considerations, including digestive tolerability, medication interactions, contraindications, and follow-up needs. Brand and route matter as well. The current Wegovy label includes semaglutide tablets and injections, while the Zepbound label describes tirzepatide injection. Other brands have different indications. A useful comparison begins by specifying the actual products being considered rather than treating each ingredient as one uniform prescription.
What did SURMOUNT-5 compare?
The SURMOUNT-5 trial randomized 751 adults with obesity without type 2 diabetes. Participants received weekly tirzepatide at a maximum tolerated dose of 10 or 15 mg, or weekly semaglutide injection at a maximum tolerated dose of 1.7 or 2.4 mg, over 72 weeks. The study was open-label, meaning participants and investigators knew which treatment was assigned.
The primary endpoint was percentage change in body weight. Randomization makes this a stronger direct comparison than placing averages from separate trials next to each other. Still, the study had defined eligibility criteria and treatment schedules. It did not include every person who might receive these medicines in clinical practice, and it was funded by the manufacturer of tirzepatide. Those features should be part of an accurate description of the evidence.
What were the main weight-loss results?
At week 72, the reported mean weight reduction was 20.2% with tirzepatide and 13.7% with semaglutide. The difference between those group averages was 6.5 percentage points. Tirzepatide also produced a larger average reduction in waist circumference in the trial. The most common adverse events in both groups were gastrointestinal, generally mild to moderate and often occurring during escalation.
These are average outcomes, not promised results for a new patient. Some participants lost more, some less, and tolerability varied. A 6.5-percentage-point difference is not the same as saying every person loses 6.5 additional pounds. For an illustrative starting weight of 200 pounds, 20.2% and 13.7% correspond mathematically to 40.4 and 27.4 pounds, but that example is arithmetic, not an individualized forecast or a treatment target.
Does the trial compare every current semaglutide option?
No. SURMOUNT-5 studied semaglutide injections at 1.7 or 2.4 mg. It did not compare tirzepatide with oral Wegovy or with the newer 7.2 mg Wegovy injection option described in the current label. Therefore, the trial should not be presented as proving superiority over every current semaglutide formulation or dose.
It also did not evaluate compounded tirzepatide against compounded semaglutide. Formulation and product approval matter when applying trial findings. The oral-versus-injection guide explains why delivery routes and milligram numbers are not interchangeable. When a comparison claims one medicine is simply “better,” ask which exact regimen was tested and whether that is the regimen actually being offered to you.
Why do different articles quote different percentages?
Trials can report results using different statistical approaches to treatment discontinuation, missing data, or continued adherence. A result intended to reflect assignment to a treatment strategy can differ from an estimate focused on continued use under specified assumptions. Choosing the largest available percentage from each study can create a misleading comparison.
Use figures from the same analysis when comparing groups, and ask what the estimate represents. Duration and population also matter: a 64-week oral study, a 72-week injection comparison, and a diabetes trial are not automatically measuring the same clinical question. This article uses the primary abstract’s 20.2% and 13.7% SURMOUNT-5 figures together. It avoids combining them with a more favorable percentage from an unrelated trial or analysis to create a stronger-looking conclusion.
What if I have type 2 diabetes?
SURMOUNT-5 excluded type 2 diabetes, so its averages should not be treated as a precise prediction for someone with that condition. Diabetes treatment decisions also include glycemic control, other medications, kidney health, cardiovascular history, hypoglycemia concerns, and the approved indications of the product under consideration.
The current Ozempic injection and Mounjaro labels describe their respective diabetes and other specified indications. Those details can matter more than a single obesity-trial percentage. Ask the clinician to explain which outcomes are priorities and which evidence supports the proposed product for your situation. Do not switch a diabetes medication solely because a weight-management comparison involved participants with a different health profile.
How do other health conditions influence the choice?
An approved indication for a particular condition can be important. Zepbound has an indication for moderate to severe OSA in adults with obesity. Wegovy has specified cardiovascular and, for its injection, MASH indications in defined populations. Ozempic injection has a kidney-related indication in adults with type 2 diabetes and chronic kidney disease. These are product-specific uses, not benefits that automatically transfer to every preparation containing the ingredient.
A history of significant gastrointestinal disease, diabetic retinopathy, previous serious allergy, pregnancy plans, or relevant thyroid cancer history also affects suitability. The clinician should review the whole medical picture. A larger mean weight reduction in one trial does not override a contraindication, a better-supported indication for another product, or a tolerability problem that makes continued treatment impractical.
Is one medicine easier to tolerate?
There is no guarantee that a particular individual will tolerate one better. Gastrointestinal symptoms were common in both SURMOUNT-5 groups. Different studies use different doses, populations, and reporting methods, so comparing adverse-event percentages from unrelated trials can be misleading. Personal experience after a carefully prescribed trial may differ from a group average.
Discuss prior nausea, vomiting, reflux, constipation, and ability to maintain nutrition. Also consider the route and routine: daily fasting tablets create different practical demands from weekly injections. A medication with impressive efficacy is not useful if the person cannot take it consistently or becomes nutritionally compromised. The semaglutide side-effect guide and tirzepatide digestive guide explain what to monitor and when symptoms require assessment.
Are there distinct medication and contraception questions?
Yes. Tirzepatide labeling includes a specific precaution for oral hormonal contraceptive users: a nonoral method or additional barrier contraception for four weeks after initiation and after each dose escalation. The birth-control guide explains that recommendation and its practical timing.
Both medicines require review of insulin, sulfonylureas, and other relevant medications, and oral semaglutide introduces particular administration and absorption considerations. Planned anesthesia or deep sedation also needs discussion because of delayed gastric emptying and aspiration concerns. The comparison should therefore include how each option fits the existing medication list and daily routine, rather than focusing only on the biological target or a weight-loss percentage.
Can I switch directly using an equivalent dose?
There is no simple milligram-for-milligram conversion between tirzepatide and semaglutide. A switch should be prescribed with attention to the previous product, dose, last administration, tolerability, treatment goal, and any interruption. Do not overlap medicines or use leftover supplies to create a transition yourself.
SURMOUNT-5 was a randomized comparison of treatment strategies, not a personalized switching study for every patient who plateaued on one medicine. It does not prove that an individual who changes medication will reproduce the average difference between groups. The existing switching article provides related context, but the actual timing and dose require the treating clinician’s plan. Ask how the new regimen will be assessed and how side effects or access problems will be handled.
For a wider comparison, see our guide to Zepbound alternatives and treatment fit. It covers current oral and injectable options, their distinct indications and practical use, and why milligrams do not provide a switching conversion.
How should cost, access, and compounded offerings be weighed?
Compare the total practical plan: ongoing availability, dispensing reliability, follow-up, and what happens if coverage or supply changes. Prices and coverage can change, so obtain current information directly for the prescription being considered. An affordable start followed by an unplanned interruption can create a different experience from a regimen that can be maintained.
The FDA compounding overview explains that compounded medicines are not FDA approved. Clinical trial percentages for branded products do not establish equivalent safety or effectiveness for a compounded offering. Ask the service to identify the actual product and explain why it is appropriate. Do not treat an ingredient name or a marketing comparison as proof that the proposed preparation is the one studied in SURMOUNT-5.
What is the most useful conclusion for a treatment visit?
Tirzepatide produced greater average weight reduction than the semaglutide injection regimen studied in SURMOUNT-5. That is a meaningful finding with clear boundaries. Choosing treatment still requires the patient’s conditions, priorities, contraindications, tolerability, route preference, and ability to continue care.
Bring a list of goals and practical concerns rather than asking only which medicine has the largest percentage. Ask which evidence applies to the exact prescription, how benefit will be measured, and what would lead to a change. The semaglutide questions guide and tirzepatide questions guide provide a starting point for that broader, individualized discussion.
Related reading
- Tirzepatide Questions: A Guide to Treatment, Safety, and Follow-Up
- Missed Tirzepatide Doses: Scheduling, Longer Gaps, and Restart Questions
- Tirzepatide Nausea and Reflux: Symptoms, Meals, and When to Get Help
- What Happens After Stopping Tirzepatide? Maintenance and Weight Regain
- Mounjaro Dosage Chart
- What To Eat On Mounjaro
- Switching From Semaglutide To Tirzepatide
For service details, see CoreAge Rx Tirzepatide information. CoreAge Rx describes this offering as compounded. Compounded medications are not FDA approved; the branded-product evidence discussed here does not establish the same safety, effectiveness, or approved uses for a compounded preparation.
Educational information. Individual treatment selection, prescription directions, and follow-up belong with the treating clinician. Linked guidance and source versions checked September 16, 2026. Medication instructions and evidence can differ by formulation and clinical use. Photographs are illustrative and do not show treatment outcomes.
